Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4453791 | 0.98 | HTR6 (0.38) | HTR6RAD52 | |
| SCHEMBL1647530 | 0.94 | HTR6 (0.36) | HTR6 | |
| SCHEMBL6274716 | 0.88 | HTR6 (0.37) | HTR6 | |
| SCHEMBL157427 | 0.82 | CYP2D6 (0.33) | HTR6 | |
| SCHEMBL2010172 | 0.82 | HTR6 (0.35) | HTR6 | |
| SCHEMBL1428236 | 0.82 | — | — | |
| SCHEMBL6487010 | 0.82 | HTR6 (0.34) | HTR6 | |
| SCHEMBL4712511 | 0.80 | CYP2D6 (0.32) | HTR6 | |
| SCHEMBL3658217 | 0.80 | CYP2D6 (0.32) | HTR6 | |
| SCHEMBL2229452 | 0.80 | CYP2D6 (0.32) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115835911-A | Imidazo [1,2-a ] pyridine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-03-21 | — | — | CN | claimed |
| CN-112673003-A | Novel pyrrolidine amine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-04-16 | — | — | CN | claimed |
| EP-1784399-B1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2011-06-15 | — | — | EP | claimed |
| JP-4674236-B2 | — | — | 2011-04-20 | — | — | JP | claimed |
| US-7910585-B2 | Pyrimidine derivatives | NOVARTIS AG (CH) | 2011-03-22 | — | — | US | claimed |
| US-7544803-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-06-09 | — | — | US | claimed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | claimed |
| US-20080293708-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | claimed |
| JP-2008510765-A | — | — | 2008-04-10 | — | — | JP | claimed |
| EP-1863804-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2007-12-12 | — | — | EP | claimed |
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | claimed |
| US-6864254-B1 | Inhibitor for 20-hete-yielding enzyme | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-03-08 | — | — | US | claimed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | claimed |
| WO-2004085421-A2 | BIOREDUCTIVELY-ACTIVATED PRODRUGS | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2004-10-07 | — | — | WO | claimed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | claimed |
| EP-0636025-B1 | COMPOUNDS USEFUL FOR TREATING ALLERGIC OR INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORP (US) | 2001-07-18 | — | — | EP | claimed |
| US-5814656-A | Selective prevention of organ injury is sepsis and shock using selective release of nitric oxide vulnerable organs | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-09-29 | — | — | US | claimed |
| EP-0191045-B1 | USE OF 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACID DERIVATIVES | ZAMBON S.p.A. (IT) | 1989-12-20 | — | — | EP | claimed |
| US-4774246-A | 6,8-DIFLUORO-4-OXO-3-CARBOXYLIC ACID DERIVATIVES | ABBOTT LABORATORIES (US) | 1988-09-27 | — | — | US | claimed |
| EP-0071892-B1 | PHOSPHOLIPID DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION OF THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-10-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | HTR6 136/4885RAD52 1600/4885 |
| US-20080293708-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | HTR6 2155/4885RAD52 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.